The Open Access Series of Imaging Studies (OASIS) is a project aimed at making neuroimaging data sets of the brain freely available to the scientific community. By compiling and freely distributing neuroimaging data sets, we hope to facilitate future discoveries in basic and clinical neuroscience.
About the OASIS Brains project
OASIS-3 and OASIS-4 are the latest releases in the Open Access Series of Imaging Studies (OASIS) that is aimed at making neuroimaging datasets freely available to the scientific community. By compiling and freely distributing this multimodal dataset generated by the Knight ADRC and its affiliated studies, we hope to facilitate future discoveries in basic and clinical neuroscience. Previously released data for OASIS-Cross-sectional (Marcus et al, 2007) and OASIS-Longitudinal (Marcus et al, 2010) have been utilized for hypothesis driven data analyses, development of neuroanatomical atlases, and development of segmentation algorithms. OASIS-3 is a longitudinal multimodal neuroimaging, clinical, cognitive, and biomarker dataset for normal aging and Alzheimer’s Disease. OASIS-4 contains MR, clinical, cognitive, and biomarker data for individuals that presented with memory complaints.
The OASIS datasets hosted by central.xnat.org provide the community with open access to a significant database of neuroimaging and processed imaging data across a broad demographic, cognitive, and genetic spectrum an easily accessible platform for use in neuroimaging, clinical, and NOTICE: OASIS Datasets Migration to NITRC-IR in Progresscognitive research on normal aging and cognitive decline.
NOTICE: OASIS Datasets Migration to NITRC-IR in Progress
Please be informed that Oasis datasets are currently undergoing migration to NITRC-IR. While you may submit your application, access will not be granted until the migration process is completed. Thank you for your understanding.
Summary: This set consists of a cross-sectional collection of 416 subjects aged 18 to 96. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 100 of the included subjects over the age of 60 have been clinically diagnosed with very mild to moderate Alzheimer’s disease (AD). Additionally, a reliability data set is included containing 20 nondemented subjects imaged on a subsequent visit within 90 days of their initial session.
Summary: This set consists of a longitudinal collection of 150 subjects aged 60 to 96. Each subject was scanned on two or more visits, separated by at least one year for a total of 373 imaging sessions. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 72 of the subjects were characterized as nondemented throughout the study. 64 of the included subjects were characterized as demented at the time of their initial visits and remained so for subsequent scans, including 51 individuals with mild to moderate Alzheimer’s disease. Another 14 subjects were characterized as nondemented at the time of their initial visit and were subsequently characterized as demented at a later visit.
Summary: OASIS-3 is a retrospective compilation of data for 1378 participants that were collected across several ongoing projects through the WUSTL Knight ADRC over the course of 30years. Participants include 755 cognitively normal adults and 622 individuals at various stages of cognitive decline ranging in age from 42-95yrs. All participants were assigned a new random identifier and all dates were removed and normalized to reflect days from entry into study. The dataset contains 2842 MR sessions which include T1w, T2w, FLAIR, ASL, SWI, time of flight, resting-state BOLD, and DTI sequences. Many of the MR sessions are accompanied by volumetric segmentation files produced through FreeSurfer processing. PET imaging from different tracers, PIB, AV45, and FDG, totaling over 2157 raw imaging scans and the accompanying post-processed files from the Pet Unified Pipeline (PUP) are also available in OASIS-3. Additionally, 451 Tau PET sessions and post-processed PUP are now available for OASIS-3 subjects in a sub-project ‘OASIS-3_AV1451’.
Summary: An additional 451 Tau PET sessions and post-processed PUP are now available for OASIS-3 subjects in a sub-project ‘OASIS-3_AV1451’.
This dataset requires a unique data request at the following link: https://sites.wustl.edu/oasisbrains/home/oasis-3/request-tau-access/
Summary: This set consists of a collection of 663 subjects aged 21 to 94. This clinical cohort was evaluated for memory disorders and dementia including clinical, csf, neurospychometric, and neuroimaging assessments.
This is a unique OASIS dataset and not an update to the OASIS-3 Longitudinal Multimodal Neuroimaging datasets.
Data Use Terms
The OASIS data are distributed to the greater scientific community under the following terms:
- You will not attempt to establish the identity of or make contact with any of the human participants included in the OASIS data. This includes, but is not limited to, facial recognition and 3D facial rendering.
- You will acknowledge the use of OASIS data and data derived from OASIS data when publicly presenting any results or algorithms that benefitted from their use. All papers, book chapters, books, posters, oral presentations, and other printed and digital presentations of results derived from OASIS data should contain the following:
- Acknowledgments: “Data provided [in part] by OASIS [insert appropriate OASIS source info]”
- OASIS-1: Cross-Sectional: Principal Investigators: D. Marcus, R, Buckner, J, Csernansky J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
- OASIS-2: Longitudinal: Principal Investigators: D. Marcus, R, Buckner, J. Csernansky, J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
- OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
- OASIS-3_AV1451: Principal Investigators: T. Benzinger, J. Morris; NIH P30 AG066444, AW00006993. AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
- OASIS-4: Clinical Cohort: Principal Investigators: T. Benzinger, L. Koenig, P. LaMontagne
- Citation: The specific publications that are appropriate to cite in any given study will depend on what OASIS data were used and for what purposes. An annotated and current list of OASIS publications is available at http://www.oasis-brains.org.
- OASIS-1: Cross-Sectional: https://doi.org/10.1162/jocn.2007.19.9.1498
- OASIS-2: Longitudinal: https://doi.org/10.1162/jocn.2009.21407
- OASIS-3: Longitudinal Multimodal Neuroimaging: https://doi.org/10.1101/2019.12.13.19014902
- OASIS-4: Clinical Cohort: https://doi.org/10.1016/j.nicl.2020.102248
- All proposed publications or presentations using Florbetapir F18 (AV45) or Flortaucipir F18 (AV1451) PET data must be submitted to Avid Radiopharmaceuticals for review and comment thirty days prior to such presentation or publication for review of intellectual property interests. See Imaging data dictionary for contact information and details.
- Acknowledgments: “Data provided [in part] by OASIS [insert appropriate OASIS source info]”
- You agree to provide the Knight ADRC upon request with information on your use of OASIS data.
- Failure to abide by these data use terms may result in termination of your right to access and use OASIS data.
Register with NITRC
Data is hosted at NITRC-IR and access to projects will be granted in NITRC after your application is reviewed by OASIS staff.